Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia

Reprod Biol Endocrinol. 2009 Aug 23:7:85. doi: 10.1186/1477-7827-7-85.

Abstract

Objective: To evaluate levels of matrix metalloproteinases (MMP) and their inhibitors (TIMP) in second trimester amniotic fluid of women with hypertensive disorders compared to normotensive women.

Study design: Amniotic fluid was obtained from 133 women undergoing genetic second trimester amniocentesis. Zymography was performed for MMP characterization and an MMP-2 ELISA kit was used to determine MMP-2 levels. TIMP-2 expression was evaluated using western blot.

Results: Mean amniotic fluid MMP-2 and TIMP-2 levels were significantly higher in women who developed a hypertensive disorder compared to normotensive women (P < 0.0004 and P < 0.01, respectively). When subdivided into subgroups, amniotic fluid from women who eventually developed preeclampsia or superimposed preeclampsia showed significantly higher MMP-2 levels than normotensive women (P < 0.05). However, no statistical difference in MMP-2 levels was found between patients with gestational hypertension and normotensive patients.

Conclusion: Higher amniotic fluid MMP-2 and TIMP-2 levels are found in women who eventually develop preeclampsia.

MeSH terms

  • Amniotic Fluid / metabolism*
  • Female
  • Humans
  • Hypertension, Pregnancy-Induced / metabolism
  • Matrix Metalloproteinase 2 / metabolism*
  • Pre-Eclampsia / metabolism*
  • Pregnancy
  • Pregnancy Trimester, Second / physiology*
  • Tissue Inhibitor of Metalloproteinase-2 / metabolism*

Substances

  • Tissue Inhibitor of Metalloproteinase-2
  • Matrix Metalloproteinase 2